| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |